Kala Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Kala Pharmaceuticals's estimated annual revenue is currently $11.6M per year.
- Kala Pharmaceuticals received $110.0M in venture funding in October 2018.
- Kala Pharmaceuticals's estimated revenue per employee is $54,299
- Kala Pharmaceuticals's total funding is $506.4M.
- Kala Pharmaceuticals's current valuation is $66.2M. (January 2022}
Employee Data
- Kala Pharmaceuticals has 214 Employees.
- Kala Pharmaceuticals grew their employee count by 0% last year.
Kala Pharmaceuticals Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 347 | -5% | $634M | N/A |
#2 | $50.9M | 253 | N/A | N/A | N/A |
#3 | $39.6M | 197 | -12% | N/A | N/A |
#4 | $11.6M | 214 | 0% | $506.4M | N/A |
#5 | $4360M | 37257 | 175% | N/A | N/A |
#6 | $16.3M | 81 | N/A | N/A | N/A |
#7 | $37.2M | 185 | N/A | N/A | N/A |
#8 | $3.2M | 16 | N/A | N/A | N/A |
#9 | $5.6M | 28 | -3% | N/A | N/A |
#10 | $888.2M | 4419 | 0% | N/A | N/A |
What Is Kala Pharmaceuticals?
Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. For more information, please visit Kala's website at www.kalarx.com.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Security,Wind Power
$506.4M
Total Funding
214
Number of Employees
$11.6M
Revenue (est)
0%
Employee Growth %
$66.2M
Valuation
N/A
Accelerator
Kala Pharmaceuticals News
Kala Pharmaceuticals, Inc., a Waltham, MA-based developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, closed $68m Series C financing. The round was led by Longitude Capital with participation from new investors OrbiMed, Vivo Capital an ...
WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has changed the time of ...
-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing -- -- KPI-012 demonstrated positive safety and efficacy results in PCED Phase 1b clinical trial -- -- Kala expects to init ...
Kala Pharmaceuticals, Inc. (KALA), today announced that the Company granted non-statutory stock options to new employees as inducement ...
Kala Pharmaceuticals, Inc. (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its ...
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) is among the top stocks that may remain in focus today as the company shares are trading 3.46% ...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $59.3M | 217 | 55% | N/A |
#2 | $64.4M | 217 | 14% | N/A |
#3 | N/A | 229 | 3% | N/A |
#4 | $63.3M | 230 | 21% | N/A |
#5 | $62.5M | 234 | 4% | N/A |
Kala Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2012-03-15 | $6.2M | Undisclosed | Lux Capital, Polaris Venture Partners | Article |
| 2013-03-01 | $11.5M | A | Crown Venture Fund LLC | Article |
| 2014-04-24 | $22.5M | B | Ysios Capital | Article |
| 2016-04-14 | $68.0M | C | Longitude Capital | Article |
| 2018-10-03 | $110.0M | Undisclosed | Athyrium Capital Management | Article |
